← Back to Screener
Aquestive Therapeutics, Inc. Common Stock (AQST)
Price$4.00
Value ScoreD
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-44.40%
Price vs S&P 500 (4W)-9.26%
VGM Score40.77
Market Capitalization$504.31M
All Metrics
Book Value / Share (Quarterly)$0.40
P/TBV (Annual)15.90x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-2.24%
Cash Flow / Share (Quarterly)$-0.36
Price vs S&P 500 (YTD)-48.70%
Gross Margin (TTM)63.45%
Net Profit Margin (TTM)-137.08%
EPS (TTM)$-0.60
10-Day Avg Trading Volume1.63M
EPS Excl Extra (TTM)$-0.60
Revenue Growth (5Y)-0.58%
EPS (Annual)$-0.78
ROI (Annual)-107.16%
Gross Margin (Annual)58.35%
Net Profit Margin (5Y Avg)-106.64%
Cash / Share (Quarterly)$0.89
Revenue Growth QoQ (YoY)65.67%
ROA (Last FY)-52.23%
Revenue Growth TTM (YoY)-7.30%
EBITD / Share (TTM)$-0.49
Operating Margin (TTM)-111.18%
Cash Flow / Share (Annual)$-0.43
P/B Ratio50.03x
P/B Ratio (Quarterly)15.59x
Net Income / Employee (Annual)$-570,000
EV / Revenue (TTM)10.39x
Net Interest Coverage (TTM)-10.98x
ROA (TTM)-49.33%
EPS Incl Extra (Annual)$-0.78
Current Ratio (Annual)3.14x
Quick Ratio (Quarterly)3.70x
3-Month Avg Trading Volume2.74M
52-Week Price Return44.09%
Revenue / Employee (TTM)$342,000
Tangible BV / Share (Quarterly)$0.40
P/S Ratio (Annual)11.32x
Asset Turnover (Annual)0.28x
52-Week High$7.55
Operating Margin (5Y Avg)-85.84%
EPS Excl Extra (Annual)$-0.78
CapEx CAGR (5Y)1.57%
26-Week Price Return-28.47%
Quick Ratio (Annual)2.92x
13-Week Price Return-2.19%
Total Debt / Equity (Annual)4.68x
Current Ratio (Quarterly)4.10x
Enterprise Value$522.33M
Revenue / Share Growth (5Y)-21.10%
Asset Turnover (TTM)0.36x
Revenue / Employee (Annual)$303,000
Inventory Turnover (Annual)3.04x
Pretax Margin (Annual)-188.09%
Cash / Share (Annual)$0.99
3-Month Return Std Dev52.80%
Gross Margin (5Y Avg)63.19%
Net Income / Employee (TTM)$-468,800
ROE (Last FY)-608.93%
Net Interest Coverage (Annual)-7.89x
EPS Basic Excl Extra (Annual)$-0.78
P/FCF (TTM)27.51x
Receivables Turnover (TTM)5.81x
Total Debt / Equity (Quarterly)4.68x
EPS Incl Extra (TTM)$-0.60
Receivables Turnover (Annual)3.63x
ROI (TTM)-47.80%
P/S Ratio (TTM)10.03x
Pretax Margin (5Y Avg)-106.55%
Revenue / Share (Annual)$0.42
Tangible BV / Share (Annual)$0.40
Price vs S&P 500 (52W)15.88%
Year-to-Date Return-37.77%
5-Day Price Return-2.43%
EPS Normalized (Annual)$-0.78
ROA (5Y Avg)-63.72%
Net Profit Margin (Annual)-188.09%
Month-to-Date Return-1.95%
Cash Flow / Share (TTM)$-0.17
EBITD / Share (Annual)$-0.66
Operating Margin (Annual)-159.50%
LT Debt / Equity (Annual)4.23x
ROI (5Y Avg)-141.26%
LT Debt / Equity (Quarterly)4.23x
EPS Basic Excl Extra (TTM)$-0.60
P/TBV (Quarterly)15.90x
P/B Ratio (Annual)15.59x
Inventory Turnover (TTM)2.41x
Pretax Margin (TTM)-137.08%
Book Value / Share (Annual)$0.40
Price vs S&P 500 (13W)-11.94%
Beta1.48x
P/FCF (Annual)134.48x
Revenue / Share (TTM)$0.41
ROE (TTM)-21.76%
52-Week Low$2.64
vGradeD
gGradeC
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.07est. -0.14
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.20
4.20
4.20
4.20
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AQSTAquestive Therapeutics, Inc. Common Stock | D | C | C | $4.00 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Aquestive Therapeutics is a specialty pharmaceutical company developing and commercializing products for central nervous system disorders and severe allergic reactions. The company markets four commercial products—Suboxone, Emylif, Ondif, and Sympazan—with pipeline candidates including Libervant Buccal Film and AQST-108. Revenue is primarily generated in the United States.